What were Titan Biotech Ltd's latest quarterly results?
Titan Biotech Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +94.3% (turning around (inflection up))
- Revenue Growth YoY: +47.6%
- Operating Margin: 19.2% (volatile)
Titan Biotech Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +114.0%Average4w StreakRe-Entry
In Week of Mar 28, 2026, Titan Biotech Ltd (Pesticides/Agrochemicals) is outperforming Nifty 500 with +114.0% relative strength. Fundamentals: Average. On a 4-week streak.
PE: At PeakRiding Wave
What's Happening
📊PE near cycle highs — limited room for further expansion
📊Debt increased 200% YoY — leverage rising
💰Trading 81% above estimated fair value — significant premium
Key Numbers
PAT Growth YoY
+94%
Inflection Up
Revenue YoY
+48%
Inflection Up
Operating Margin
19.2%
+649 bps YoY
PE Ratio
66.2
Current Price
₹436
Dividend Yield
0.09%
Fundamental Score
48/100
Average
3Y PAT CAGR
0%
Market Cap
1.8K Cr
Valuation
Significantly Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
What Is Titan Biotech Ltd's Management Guidance?
Forward-looking targets from management
Management Tone: CAUTIOUS
How Fast Is Titan Biotech Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +48% | +8% | Inflection Up |
| PAT (Net Profit) | +94% | 0% | Inflection Up |
| OPM | 19.2% | +649 bps | Volatile |
Frequently Asked Questions: Titan Biotech Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Titan Biotech Ltd's profit growing or declining?
Titan Biotech Ltd's profit is growing with an turning around (inflection up) trend.
- PAT Growth YoY: +94.3% (latest quarter)
- PAT Growth QoQ: +9.9% (sequential)
- 3-Year PAT CAGR: 0.0%
- Trend: Turning around (inflection up) — consistent growth pattern
What is Titan Biotech Ltd's revenue growth trend?
Titan Biotech Ltd's revenue growth trend is turning around (inflection up).
- Revenue Growth YoY: +47.6%
- Revenue Growth QoQ: +4.0% (sequential)
- 3-Year Revenue CAGR: +8.0%
How is Titan Biotech Ltd's operating margin trending?
Titan Biotech Ltd's operating margin is volatile.
- Current OPM: 19.2%
- OPM Change YoY: +6.5% basis points
- OPM Change QoQ: +2.0% basis points
What is Titan Biotech Ltd's 3-year profit and revenue CAGR?
Titan Biotech Ltd's long-term compounding rates
- 3-Year Profit CAGR: 0.0%
- 3-Year Revenue CAGR: +8.0%
Is Titan Biotech Ltd's growth accelerating or decelerating?
Titan Biotech Ltd's earnings growth is turning around (inflection up) with positive momentum on a sequential basis.
- YoY Acceleration: +78.5% bps
- Sequential Acceleration: -3.2% bps
What is Titan Biotech Ltd's trailing twelve month (TTM) performance?
Titan Biotech Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹27 Cr
- TTM PAT Growth: +20.9% YoY
- TTM Revenue: ₹193 Cr
- TTM Revenue Growth: +19.4% YoY
- TTM Operating Margin: 17.4%
Is Titan Biotech Ltd overvalued or undervalued?
Titan Biotech Ltd appears significantly overvalued based on our fair value analysis.
- Valuation Signal: Significantly Overvalued
- Current PE: 66.2x
- Price-to-Book: 10.8x
What is Titan Biotech Ltd's current PE ratio?
Titan Biotech Ltd's current PE ratio is 66.2x.
- Current PE: 66.2x
- Market Cap: 1.8K Cr
- Dividend Yield: 0.09%
How does Titan Biotech Ltd's valuation compare to its history?
Titan Biotech Ltd's current PE is 66.2x.
- Current PE: 66.2x
- Valuation Assessment: Significantly Overvalued
What is Titan Biotech Ltd's price-to-book ratio?
Titan Biotech Ltd's price-to-book ratio is 10.8x.
- Price-to-Book (P/B): 10.8x
- Book Value per Share: ₹40
- Current Price: ₹436
Is Titan Biotech Ltd a fundamentally strong company?
Titan Biotech Ltd is rated Average with a fundamental score of 47.51/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +47.6% (10% weight)
- PAT Growth YoY: +94.3% (10% weight)
- PAT Growth QoQ: +9.9% (10% weight)
- Margins stable (10% weight)
Is Titan Biotech Ltd debt free?
Titan Biotech Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹3 Cr
What is Titan Biotech Ltd's return on equity (ROE) and ROCE?
Titan Biotech Ltd's return ratios over recent years
- FY2023: ROCE 27.0%
- FY2024: ROCE 25.0%
- FY2025: ROCE 17.0%
Is Titan Biotech Ltd's cash flow positive?
Titan Biotech Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹20 Cr
- Free Cash Flow (FCF): ₹10 Cr
- CFO/PAT Ratio: 91% (strong cash conversion)
What is Titan Biotech Ltd's dividend yield?
Titan Biotech Ltd's current dividend yield is 0.09%.
- Dividend Yield: 0.09%
- Current Price: ₹436
Who holds Titan Biotech Ltd shares — promoters, FII, DII?
Titan Biotech Ltd's shareholding pattern (Dec 2025)
- Promoters: 55.8%
- DII (Domestic): 0.0%
- Public: 44.2%
Is promoter holding increasing or decreasing in Titan Biotech Ltd?
Titan Biotech Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 55.8% (Dec 2025)
- Previous Quarter: 55.8% (Sep 2025)
- Change: 0.00% (stable)
How long has Titan Biotech Ltd been outperforming Nifty 500?
Titan Biotech Ltd has been outperforming Nifty 500 for 4 consecutive weeks, indicating building momentum.
Is Titan Biotech Ltd a new momentum entry or an established outperformer?
Titan Biotech Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.
What is Titan Biotech Ltd's management guidance for growth?
Titan Biotech Ltd's management has provided the following forward guidance
- Management tone: cautious
Is Titan Biotech Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Titan Biotech Ltd may be worth studying
- Earnings growing at +94.3% YoY
- Cash flow is positive — CFO ₹20 Cr
What is the investment thesis for Titan Biotech Ltd?
Titan Biotech Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +47.6% YoY
Risk Factors (Bear Case)
- Appears significantly overvalued
What is the future outlook for Titan Biotech Ltd?
Titan Biotech Ltd's forward outlook based on current data signals
- Earnings Trend: turning around (inflection up)
- Revenue Trend: turning around (inflection up)
- Margin Trend: volatile
- Valuation: Significantly Overvalued
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.